Hai cercato la traduzione di metabolizzaturi da Maltese a Inglese

metabolizzaturi ħżiena
poor metabolisers

metabolizzaturi batuti ta’ cyp2c9
cyp2c9 poor metabolizers

mistenni fil-metabolizzaturi estensivi ta’
expected in cyp2c19 poor metabolisers:

metabolizzaturi dgħajfa magħrufa ta’ cyp2d6
known cyp2d6 poor metabolisers

metabolizzaturi mhux daqstant tajbin ta ’ cyp2c9:
cyp2c9 poor metabolizers:

john’ s wort jagħmel induzzjoni ta ’ l- enzimi metabolizzaturi.
this is due to induction of metabolising enzymes by st john’ s wort.

f’metabolizzaturi intermedji (ims) u metabolizzaturi estensivi (ems):
in intermediate (ims) and extensive metabolisers (ems):

dan minħabba l- induzzjoni ta ’ l- enzimi metabolizzaturi permezz ta ’ st.
this is due to the induction of metabolising enzymes by st john’s wort.

ngħidu aħna, 15-20 % tal-popolazzjonijiet asjatiċi aktarx li jkunu metabolizzaturi ħżiena.
for example, 15-20 % of asian populations may be expected to be poor metabolisers.

l- effetti ta ’ desloratadine f’ metabolizzaturi dgħajfin li għandhom < sentejn ma ġewx studjati.
the effects of aerius syrup in poor metabolisers < 2 years of age have not been studied.

l- effetti ta ’ desloratadine f’ metabolizzaturi dgħajfin ta ’ anqas minn sentejn ma kienux studjati.
the effects of aerius syrup in poor metabolizers < 2 years of age have not been studied.

suġġetti li huma metabolizzaturi eterozigoti estensivi għandhom, bħala medja, esponiment għal voriconazole darbtejn ogħla mill- metabolizzaturi emozigoti estensivi.
subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.

eliglustat huwa kontraindikat ukoll f’pazjenti li huma metabolizzaturi dgħajfa ta’ cyp2d6 li qed jieħdu inibitur qawwi ta’ cyp3a.
eliglustat is also contraindicated in patients who are cyp2d6 poor metabolisers taking a strong cyp3a inhibitor.

metabolizzaturi ultra-rapidi (ultra-rapid metabolisers, urms), u metabolizzaturi indeterminati ta’ cyp2d6
cyp2d6 ultra-rapid metabolisers (urms) and indeterminate metabolisers

perċentwal żgħir tal- popolazzjoni għandhom livelli għoljin ta ’ l- enzima cyp2d6 (metabolizzaturi mgħaġġla ħafna).
the information below

fil-każ tal-kawkasi u s-suwed il-prevalenza ta' metabolizzaturi ħżiena hija 3-5 %.
for caucasians and blacks the prevalence of poor metabolisers is 3-5%.

l-esponiment kien l-istess fl-adulti u metabolizzaturi dgħajfin pedjatriċi meta kkurati b’dożi xierqa għall-età tagħhom.
exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses.

għal pazjenti li ġisimhom ikisser il-mediċina bil-mod (metabolizzaturi dgħajfa), id-doża rakkomandata hija kapsula 1 darba kuljum.
for patients whose body breaks down the medicine slowly (poor metabolisers), the recommended dose is 1 capsule once a day.

metabolizzaturi dgħajfa ta ’ cyp2d6 f’ metabolizzaturi dgħajfa ta ’ cyp2d6 il- metaboliżmu ta ’ darifenacin huwa medjat prinċipalment permezz ta ’ cyp3a4.
17 cyp2d6 poor metabolisers the metabolism of darifenacin in cyp2d6 poor metabolisers is principally mediated by cyp3a4.